Dune Medical Moves U.S. Headquarters

Dune Medical Devices Inc. has moved its U.S. headquarters in Boston, Mass., to the city’s so-called “innovation district” located on the South Boston waterfront. The relocation followed the recent U.S. Food and Drug Administration (FDA) approval of its flagship product, the MarginProbe System, an intra-operative tissue assessment device for early-stage breast cancer surgery.

“The FDA approval of MarginProbe in the U.S. is a major milestone for Dune, and an opportune time to upgrade our facilities in anticipation of robust growth in 2013,” said Dan Levangie, CEO. “The innovation district was an attractive location due to its reputation as a mecca for emerging medical technology in the Boston area.”

The new headquarters will accommodate the expansion of several departments throughout 2013, including operations, sales and marketing, and clinical and regulatory, to support the commercialization of MarginProbe in the United States and ongoing exploration of the technology’s potential applications.

MarginProbe has been available in Europe since 2008 and is now available in select locations throughout the United States, with national availability expected in early this year. The MarginProbe system is designed to deliver real-time cancer detection in the operating room for a simple and immediate assessment of cancer on the margin of excised tissue. According to Dune, in a randomized study of 300 breast cancer patients in Israel, the reoperation rate was reduced by 56 percent when MarginProbe was used.

Dune Medical Devices, whose global headquarters are in Israel, provides proprietary tissue characterization technology for the identification of cancerous tissue. The company hopes to eventually apply its technology to a broader range of surgical and diagnostic applications.